{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:50:36Z","timestamp":1784137836824,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Up to half of patients with localized prostate cancer experience biochemical relapse within 10 years after definitive radiotherapy. The aim of this prospective study was to investigate the toxicity, dose to the organs at risk (OARs), and efficacy of dose-intensified focal salvage radiotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Material<\/jats:title><jats:p>Thirty-three patients (median age 68.8 years) with histologically confirmed relapse after primary definitive radiotherapy were enrolled between 2012 and 2019. No patients had metastases at imaging or in bone marrow aspiration. Twenty-three patients were treated with high dose-rate brachytherapy to the recurrent tumor, defined at multiparametric MRI, with 3 fractions of 10 Gy with two weeks interval, and 10 patients by stereotactic body radiotherapy with 35 Gy to the local recurrence and 25 Gy to the whole prostate in 5 fractions. We used the RTOG-scoring system to grade genitourinary (GU) and gastrointestinal toxicity (GI) at three months (acute), and at 12, 24, and 36 months (late). Dose-volume histogram parameters to the local recurrence and the OARs were obtained and 2 Gy equivalent (EQD2) total dose was calculated using the linear-quadratic model with \u03b1\/\u03b2 = 3 Gy. Efficacy was assessed by the progression-free interval and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow-up time was 81 months (range 21\u2013115). The cumulative moderate to severe GI and GU toxicities were 3.0% (1\/33) and 15.2% (5\/33). Six patients had grade 1 acute GI toxicity, none had grade 2 or 3. One patient had grade 3 acute GU toxicity, two had grade 2, and fourteen had grade 1. One patient had late GI toxicity grade 2 and eight had grade 1. Four patients had late GU toxicity grade 2 and eight had grade 1. No patients had grade 3 late toxicity. The mean total D90 to the recurrent tumor was 77.7 \u00b1 17.0 Gy. The mean total rectum D2cc was 17.0 \u00b1 7.9 Gy and the mean total urethra D0.1cc was 29.1 \u00b1 8.2 Gy. Twenty-eight patients had re-irradiation without androgen deprivation therapy (ADT). Nine of these are still relapse-free and 10 had a recurrence-free interval longer than 2 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The toxicity of salvage radiotherapy was mild to moderate. One-third of the patients achieved long-term stable disease without ADT and one-third had a recurrence-free interval longer than 2 years. Some patients progressed rapidly and probably did not benefit from re-irradiation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.861127","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:44:19Z","timestamp":1649328259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome"],"prefix":"10.3389","volume":"12","author":[{"given":"Una","family":"Ryg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Seierstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Brennhaug","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taran Paulsen","family":"Hellebust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Holth","family":"Djupvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Hydal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut H\u00e5kon","family":"Hole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Lilleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of Different Definitions of Biochemical Failure After External Beam Radiotherapy Changes Conclusions About Relative Treatment Efficacy for Localized Prostate Cancer","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.10.004","article-title":"Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes","volume":"71","author":"Cahlon","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.12.070","article-title":"Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406","volume":"83","author":"Michalski","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.04.003","article-title":"Management of High-Risk Prostate Cancer: Radiation Therapy and Hormonal Therapy","volume":"39","author":"Nomiya","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.07.004","article-title":"Prognostic Factors for Biochemical Recurrence More Than 10 Years After Radical Prostatectomy","volume":"197","author":"Liesenfeld","year":"2017","journal-title":"J\u00a0Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A Systematic Review and Meta-Analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.04.022","article-title":"A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis","volume":"5","author":"Corkum","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse After Prostate Cancer Radiotherapy: An ESTRO ACROP Delphi Consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.04.032","article-title":"Mastering the Landscape of Postradiation Local Prostate Salvage Therapy","volume":"80","author":"Zheng","year":"2021","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence After External Beam Radiation Therapy (NRG Oncology\/Xxxx)","volume":"112","author":"Crook","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102176","article-title":"Outcomes and Toxicities of Re-Irradiation for Prostate Cancer: A Systematic Review on Behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"95","author":"Munoz","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.01.075","article-title":"Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era","volume":"21","author":"D'amico","year":"2003","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0284185118810977","article-title":"Localization of Radio-Recurrence Within the Prostate: Anti-3-18F-FACBC PET\/CT Compared With Multiparametric MRI Using Histopathology as Reference Standard","volume":"60","author":"Tulipan","year":"2019","journal-title":"Acta Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR Prostate MR Guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"B15","article-title":"[High Dose Rate Brachytherapy in Prostate Cancer in Norway]","volume":"128","author":"Raabe","year":"2008","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-c","article-title":"Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.09.039","article-title":"A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology\/RTOG-0526)","volume":"103","author":"Crook","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.12.040","article-title":"Germline Variants Disrupting microRNAs Predict Long-Term Genitourinary Toxicity After Prostate Cancer Radiation","volume":"167","author":"Kishan","year":"2022","journal-title":"Radiother Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.04.111","article-title":"Patterns of Local Failure Following Radiation Therapy for Prostate Cancer","volume":"194","author":"Jalloh","year":"2015","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24059","article-title":"Impact of Radiation Dose on Recurrence in High-Risk Prostate Cancer Patients","volume":"80","author":"Deek","year":"2020","journal-title":"Prostate"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and Bladder Dose-Effect Relations for Late Genitourinary Toxicity Following External Beam Radiotherapy for Prostate Cancer in the FLAME Trial","volume":"167","author":"Groen","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.861127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:44:23Z","timestamp":1649328263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.861127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":21,"alternative-id":["10.3389\/fonc.2022.861127"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.861127","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"article-number":"861127"}}